What is KALA's P/E ratio?

Kala Pharmaceuticals Inc (KALA) currently trades at a P/E ratio of 20.95.

Kala Pharmaceuticals Inc reports a Return on Equity (ROE) of -182.64%.

What is KALA's dividend yield?

Kala Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is KALA's Quality Score?

Our AI rates KALA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KALA?

Our AI Timing Score for KALA is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KALA belong to?

Kala Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Kala Pharmaceuticals Inc (KALA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

KALA AI Analysis Summary

Our AI summary for KALA: Kala Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 20.95, ROE of -182.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KALA

Kala Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 0.70

-0.04 (-5.65%) Day Change

Watchlist Portfolio Compare Chart

20.95

P/E

0.14

D/E

-182.6%

ROE

-159.6%

ROA

0.00%

Div Yield

-0.41

PEG

KALA PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.70 Price -0.04 (-5.65%) Day Change	NEWS SCORE: 89

KALA, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.70
PBV / Sector	1.34 / 44,105.10 GOOD
Earning Per Share	-0.96

PE / Sector	20.95 / 19.37
PEG or PE/Growth / Sector	-0.41 / 1.06
Average 1M Daily Value	0.13 M GREAT
Average 1W Daily Value	0.06 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	-1,151.64 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-159.56 / 185,260.64
ROA Average (%) / Sector	-128.06 / 36,684.64
ROA Change Average (%) / Sector	75.96 / 422,221.42 GREAT
ROE (%) / Sector	-182.64 / 243,761.81
ROE Average (%) / Sector	-335.83 / 48,758.38
ROE Change Average (%) / Sector	16.11 / 424,967.86 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:13
Symbol	KALA
Name	KALA PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	19.34 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	14.37 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1167 Massachusetts Avenue, Arlington, MA, United States, 02476

Phone: 781 996 5252

Website: https://www.kalarx.com

Sector: Healthcare >> Biotechnology

Description: KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.